

Nilufar Mossaheb

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5908020/publications.pdf>

Version: 2024-02-01

73
papers

2,278
citations

236925
25
h-index

223800
46
g-index

77
all docs

77
docs citations

77
times ranked

3149
citing authors

#	ARTICLE	IF	CITATIONS
1	Reduced Serotonin-1A Receptor Binding in Social Anxiety Disorder. <i>Biological Psychiatry</i> , 2007, 61, 1081-1089.	1.3	276
2	Effect of 3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 19.	11.0	216
3	Emotion Recognition in Individuals at Clinical High-Risk for Schizophrenia. <i>Schizophrenia Bulletin</i> , 2012, 38, 1030-1039.	4.3	149
4	Lithium in drinking water and suicide mortality. <i>British Journal of Psychiatry</i> , 2011, 198, 346-350.	2.8	142
5	The Community Assessment of Psychic Experience (CAPE) questionnaire as a screening-instrument in the detection of individuals at ultra-high risk for psychosis. <i>Schizophrenia Research</i> , 2012, 141, 210-214.	2.0	106
6	Effects of Olanzapine and Ziprasidone on Glucose Tolerance in Healthy Volunteers. <i>Neuropsychopharmacology</i> , 2008, 33, 1633-1641.	5.4	91
7	In vivo imaging of serotonin transporter occupancy by means of SPECT and [123I]ADAM in healthy subjects administered different doses of escitalopram or citalopram. <i>Psychopharmacology</i> , 2006, 188, 263-272.	3.1	76
8	The role of estrogen and progesterone in depression after birth. <i>Journal of Psychiatric Research</i> , 2007, 41, 273-279.	3.1	61
9	Higher serotonin transporter occupancy after multiple dose administration of escitalopram compared to citalopram: an [123I]ADAM SPECT study. <i>Psychopharmacology</i> , 2007, 191, 333-339.	3.1	58
10	Facial and vocal affect perception in people at ultra-high risk of psychosis, first episode schizophrenia and healthy controls. <i>Microbial Biotechnology</i> , 2012, 6, 450-454.	1.7	57
11	Omega-3 Fatty Acid Supplementation in Adolescents with Borderline Personality Disorder and Ultra-High Risk Criteria for Psychosis: A Post Hoc Subgroup Analysis of a Double-Blind, Randomized Controlled Trial. <i>Canadian Journal of Psychiatry</i> , 2013, 58, 402-408.	1.9	55
12	NEURAPRO study protocol: a multicentre randomized controlled trial of omega-3 fatty acids and cognitive-behavioural case management for patients at ultra high risk of schizophrenia and other psychotic disorders. <i>Microbial Biotechnology</i> , 2017, 11, 418-428.	1.7	55
13	Usefulness of the CAPE-P15 for detecting people at ultra-high risk for psychosis: Psychometric properties and cut-off values. <i>Schizophrenia Research</i> , 2017, 189, 69-74.	2.0	54
14	Differences in the dynamics of serotonin reuptake transporter occupancy may explain superior clinical efficacy of escitalopram versus citalopram. <i>International Clinical Psychopharmacology</i> , 2009, 24, 119-125.	1.7	49
15	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	1.3	48
16	Comprehension of metaphors in patients with schizophrenia-spectrum disorders. <i>Comprehensive Psychiatry</i> , 2014, 55, 928-937.	3.1	47
17	Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2019, 206, 67-74.	2.0	46
18	History of trauma and the association with baseline symptoms in an Ultra-High Risk for psychosis cohort. <i>Psychiatry Research</i> , 2013, 210, 75-81.	3.3	41

#	ARTICLE	IF	CITATIONS
19	Neuropathological Variability within a Spectrum of <sc>NMDAR</sc>â€Encephalitis. Annals of Neurology, 2021, 90, 725-737.	5.3	35
20	Erythrocyte polyunsaturated fatty acid levels in young people at ultra-high risk for psychotic disorder and healthy adolescent controls. Psychiatry Research, 2015, 228, 174-176.	3.3	34
21	Effect of omega-3 fatty acids for indicated prevention of young patients at risk for psychosis: When do they begin to be effective?. Schizophrenia Research, 2013, 148, 163-167.	2.0	31
22	Polyunsaturated fatty acids in emerging psychosis: a safer alternative?. Microbial Biotechnology, 2014, 8, 199-208.	1.7	28
23	The Ultra-High-Risk for psychosis groups: Evidence to maintain the status quo. Schizophrenia Research, 2018, 195, 543-548.	2.0	28
24	Pharmacokinetics and Elimination of Quetiapine, Venlafaxine, and Trazodone During Pregnancy and Postpartum. Journal of Clinical Psychopharmacology, 2007, 27, 720-722.	1.4	27
25	Do patients with different psychiatric disorders show altered social decision-making? A systematic review of ultimatum game experiments in clinical populations. Cognitive Neuropsychiatry, 2018, 23, 117-141.	1.3	27
26	Comparison of erythrocyte omega-3 index, fatty acids and molecular phospholipid species in people at ultra-high risk of developing psychosis and healthy people. Schizophrenia Research, 2020, 226, 44-51.	2.0	27
27	On the relationship of first-episode psychosis to the amphetamine-sensitized state: a dopamine D2/3 receptor agonist radioligand study. Translational Psychiatry, 2020, 10, 2.	4.8	25
28	Psychotic-Like Experiences: A Challenge in Definition and Assessment. Frontiers in Psychiatry, 2021, 12, 582392.	2.6	25
29	Mirtazapine and Breastfeeding: Maternal and Infant Plasma Levels. American Journal of Psychiatry, 2007, 164, 348-349.	7.2	22
30	Does specific psychopathology predict development of psychosis in ultra high-risk (UHR) patients?. Australian and New Zealand Journal of Psychiatry, 2013, 47, 380-390.	2.3	22
31	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. Frontiers in Psychiatry, 2019, 10, 393.	2.6	22
32	Late-Onset Depression in Elderly Subjects From the Vienna Transdanube Aging (VITA) Study. Journal of Clinical Psychiatry, 2009, 70, 500-508.	2.2	22
33	Are Specific Symptoms of Depression Predictive of Alzheimerâ€™s Dementia?. Journal of Clinical Psychiatry, 2012, 73, 1009-1015.	2.2	21
34	Opening the Black Box of Cognitive-Behavioural Case Management in Clients with Ultra-High Risk for Psychosis. Psychotherapy and Psychosomatics, 2017, 86, 292-299.	8.8	20
35	Striatal D2 receptor occupancy in bipolar patients treated with olanzapine. European Neuropsychopharmacology, 2007, 17, 102-107.	0.7	18
36	Polyunsaturated Fatty Acids in Emerging Psychosis. Current Pharmaceutical Design, 2012, 18, 576-591.	1.9	16

#	ARTICLE	IF	CITATIONS
37	Role of aripiprazole in treatment-resistant schizophrenia. <i>Neuropsychiatric Disease and Treatment</i> , 2012, 8, 235.	2.2	16
38	The Impact of Sex Differences on Odor Identification and Facial Affect Recognition in Patients with Schizophrenia Spectrum Disorders. <i>Frontiers in Psychiatry</i> , 2018, 9, 9.	2.6	16
39	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16
40	Interaction between serotonin 5-HT _{2A} receptor gene and dopamine transporter (DAT1) gene polymorphisms influences personality trait of persistence in Austrian Caucasians. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 417-424.	2.6	14
41	Affect recognition and functioning in putatively prodromal individuals. <i>Schizophrenia Research</i> , 2013, 147, 404-405.	2.0	10
42	Fulminant Onset of Valproate-Associated Hyperammonemic Encephalopathy. <i>American Journal of Psychiatry</i> , 2019, 176, 900-903.	7.2	10
43	Omega-3 fatty acids and neurocognitive ability in young people at ultra-high risk for psychosis. <i>Microbial Biotechnology</i> , 2021, 15, 874-881.	1.7	10
44	Binding kinetics of ¹²³ I[ADAM] in healthy controls: a selective SERT radioligand. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 211.	2.1	8
45	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	2.0	8
46	Basic symptoms in young people at ultra-high risk of psychosis: Association with clinical characteristics and outcomes. <i>Schizophrenia Research</i> , 2020, 216, 255-261.	2.0	8
47	Cognitive functioning in ultra-high risk for psychosis individuals with and without depression: Secondary analysis of findings from the NEURAPRO randomized clinical trial. <i>Schizophrenia Research</i> , 2020, 218, 48-54.	2.0	8
48	Characterization and prediction of clinical pathways of vulnerability to psychosis through graph signal processing. <i>ELife</i> , 2021, 10, .	6.0	7
49	Case report: Intestinal atonia as an unusual symptom of malignant catatonia responsive to electroconvulsive therapy. <i>Schizophrenia Research</i> , 2006, 84, 178-179.	2.0	6
50	Predictors of longer-term outcome in the Vienna omega-3 high-risk study. <i>Schizophrenia Research</i> , 2018, 193, 168-172.	2.0	6
51	Aripiprazole-Induced Psychosis. <i>Journal of Clinical Psychiatry</i> , 2007, 68, 1445-1446.	2.2	6
52	Duration of untreated psychosis in a high-income versus a low- and middle-income region. <i>Australian and New Zealand Journal of Psychiatry</i> , 2013, 47, 1176-1182.	2.3	5
53	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. <i>Schizophrenia Bulletin</i> , 2018, 44, S132-S133.	4.3	5
54	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5

#	ARTICLE	IF	CITATIONS
55	Favourable results in treatment-resistant schizophrenic patients under combination of aripiprazole with clozapine. World Journal of Biological Psychiatry, 2010, 11, 502-505.	2.6	4
56	Psychotic-like experiences in esoterism: A twilight zone?. Schizophrenia Research, 2018, 193, 240-243.	2.0	4
57	Machine learning based prediction and the influence of complement “ Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. Brain, Behavior, and Immunity, 2022, 103, 50-60.	4.1	4
58	Changes in triglyceride levels in ultra-high risk for psychosis individuals treated with omega-3 fatty acids. Microbial Biotechnology, 2018, 12, 30-36.	1.7	3
59	Aripiprazole-induced psychosis: a case report of reexposure by stepwise up-titration. Journal of Clinical Psychiatry, 2007, 68, 1445-6.	2.2	3
60	Bipolar disorder susceptibility region on chromosome 3q29 not confirmed in a case-control association study. World Journal of Biological Psychiatry, 2011, 12, 309-315.	2.6	2
61	T9. CROSS-SECTIONAL ASSOCIATION OF MEMBRANE FATTY ACID COMPOSITION AND PSYCHOPATHOLOGY IN THE NEURAPRO-E STUDY. Schizophrenia Bulletin, 2018, 44, S116-S116.	4.3	2
62	T104. PSYCHOTIC-LIKE EXPERIENCES AND PROBLEMATIC GAMING BEHAVIOR IN ONLINE GAME FORUMS. Schizophrenia Bulletin, 2020, 46, S270-S270.	4.3	2
63	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. Brain, Behavior, and Immunity, 2022, 99, 147-156.	4.1	2
64	Twelve-Month Cognitive Trajectories in Individuals at Ultra-High Risk for Psychosis: A Latent Class Analysis. Schizophrenia Bulletin Open, 2022, 3, .	1.7	2
65	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. Schizophrenia Bulletin, 2018, 44, S228-S228.	4.3	1
66	S136. A NOVEL APPROACH FOR DEVELOPING PREDICTION MODEL OF TRANSITION TO PSYCHOSIS: DYNAMIC PREDICTION USING JOINT MODELLING. Schizophrenia Bulletin, 2018, 44, S378-S379.	4.3	1
67	O8.8. NEUROCOGNITION IN ULTRA-HIGH-RISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2018, 44, S99-S99.	4.3	1
68	Metacognitive beliefs in individuals at risk for psychosis: a systematic review and meta-analysis of sex differences. Neuropsychiatry, 2020, 34, 108-115.	2.5	1
69	Long-Chain Omega-3 Fatty Acids and Psychotic Disorders. , 2013, , 149-178.		0
70	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2020, 46, S244-S245.	4.3	0
71	S102. DIAGNOSTIC CHALLENGES AT TIME OF INPATIENT ADMISSION: DIAGNOSTIC SHIFTS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS. Schizophrenia Bulletin, 2020, 46, S73-S73.	4.3	0
72	S242. BEFORE AND AFTER: PATHWAYS TO CARE AND AFTER DISCHARGE AT A NEWLY ESTABLISHED EARLY PSYCHOSIS INPATIENT UNIT. Schizophrenia Bulletin, 2020, 46, S131-S131.	4.3	0

#	ARTICLE	IF	CITATIONS
73	Editorial: Clinical High Risk for Psychosis: From Epidemiological Findings to Neurobiological Underpinnings of Treatment Response and Outcome. <i>Frontiers in Psychiatry</i> , 2021, 12, 790810.	2.6	0